Guggulsterone: A Comprehensive Reference
1. Identity: Chemical and Botanical Profile
Chemical names and formula. Guggulsterone (pregna-4,17-diene-3,16-dione; C21H28O2) is an effective phytosterol isolated from the gum resin of the tree Commiphora wightii (Family Burseraceae). The full IUPAC name is (8R,9S,10R,13S,14S)-17-Ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione, with a molecular weight of 312.45 g/mol. The compound is also described as 4,17(20)-pregnadiene-3,16-dione, and is a plant sterol present in the resin of Commiphora mukul.
Stereoisomers. Guggulsterone exists as two stereoisomers, E-guggulsterone (trans) and Z-guggulsterone (cis), differing in the configuration at the exocyclic double bond between C-17 and C-20. It is an aromatic steroidal ketonic compound obtained from the vertical resin ducts and canals of the bark of Commiphora wightii (Arn.) Bhandari, belonging to the family Burseraceae. Both isomers are present in the raw oleo-gum-resin in variable ratios depending on environmental and geographic factors, as demonstrated by HPLC fingerprinting studies. Present findings have revealed the role of environmental factors on biosynthesis of guggulsterone isomers under natural conditions. By HPLC-based fingerprinting, the botanical identity of the plant can be linked with its biochemical profile, and it allows for the determination of variations in the guggul resin component's content in different collected accessions grown and harvested at different climatic conditions.
Botanical source.
Commiphora wightii is an important medicinal plant from India, known as "Guggul" or "Indian bdellium," recognized for its oleo-gum-resin, which has been valued in Ayurveda for over 3,000 years. It is primarily found in arid regions, particularly in the Thar desert, and is noted for its potential in large-scale cultivation and essential oil production.
The plant is a shrub reaching 3 m in height with crooked, knotty branches ending in sharp spines. Commiphora wightii is sought for its gummy resin, which is harvested from the plant's bark through the process of tapping; in India and Pakistan, guggul is cultivated commercially.
Synonyms and related names. Synonyms for the plant include: Guggul, Gum guggul, Indian bdellium-tree, Indian bdellium, and Commiphora mukul. The resin of C. wightii, known as gum guggulu, has a fragrance nearly identical to myrrh, and it is the same product that was known in Hebrew, ancient Greek, and Latin sources as bdellium, commonly used in incense and perfumes for centuries.
Primary extract: guggulipid. Guggulsterone is the primary active ingredient in guggulipid, a standardized extract from the resin of Commiphora wightii. Since 1988, guggulipid has been marketed in India as a hypolipidemic agent and is prescribed for the treatment of hyperlipidemia.
2. Traditional and Historical Use
Ayurveda and antiquity. The extract of gum guggul, called gugulipid, guggulipid, or guglipid, has been used in Unani and Ayurvedic medicine for nearly 3,000 years in India. Guggul is mentioned in Ayurvedic texts dating back to 600 BC. The earliest reference to guggulu is found in the Atharvaveda. It provides "Guggul," an oleo-gum-resin mentioned by Sushruta 3,000 years ago as being a valuable drug in Ayurveda.
Traditional indications. Gum resin from Commiphora wightii has been used for centuries in Ayurveda to treat internal tumors, obesity, liver disorders, malignant sores and ulcers, urinary complaints, intestinal worms, leucoderma (vitiligo), sinuses, edema, and sudden paralytic seizures. This gum resin has been used for centuries in Ayurvedic medicine to treat obesity, arthritis, and hyperlipidemia.
Unani medicine. Guggulsterone is responsible for many of the properties of guggul, which is widely used as traditional medicine in the Ayurveda and Unani systems of medicine.
Classical preparations and purification. In Sharangadhara Samhita, Guggulu Kalpana is described under Vati Kalpana. A screening through Brihattrayee revealed that guggulu was preferred to be dispensed internally in the form of liquid or semi-liquid or semi-solids. Guggulu in Vati (tablet) form entered the field of therapeutics after the 11th century AD (Chakradutta). Later on, guggulu was widely used in Vati form. Ayurveda advocates that guggulu must be administered only after purification (Shodhana). The current trend of Ayurvedic pharmaceuticals mainly shows the use of guggulu in the form of Gutika or Vati.
Ayurvedic purification (Shodhana). In order to overcome unwanted effects of raw guggulu, Ayurveda describes a number of purification processes (Shodhan vidhi) using different fluids (dravyas), which not only address adverse effects but also enhance therapeutic activity. According to Ayurvedic texts, guggulu must be purified before incorporating into formulations. During the process of shodhan, guggulu is treated with specific materials of biological origin, such as herbal juices, cow urine, and cow milk. It is possible that some properties (chemical and biological) of shodhan materials are added to guggulu during the process, and that some toxic or harmful constituents of raw guggulu are neutralized, detoxified, or removed.
Classical polyherbal formulations. In classical Ayurveda, formulations containing guggul—such as "Triphala Guggul," "Kaishore Guggul," and "Yograj Guggul"—were prescribed for "Medoroga" (disorders of fat metabolism), joint discomfort, and skin eruptions. There are a large number of commercial polyherbal anti-inflammatory formulations which use guggulu as the chief ingredient.
Incense and religious use. Guggulu is used not only as medicine but also in religious rituals. The gum can be purchased in a loosely packed form called dhoop, an incense from India, which is burned over hot coals.
3. Key Constituents and Active Compounds
Guggulsterone as the primary bioactive. Guggulsterone has been identified as one of the major active components of this gum resin. Guggulsterone is a plant sterol isolated from the gum resin of some members of the family Burseraceae. The gum resin from these plants has been used for thousands of years to treat various ailments like obesity, tumors, intestinal worms, liver problems, cancer, and leucoderma.
Other phytochemical classes. The raw oleo-gum-resin of Commiphora wightii is chemically complex and extends beyond guggulsterones. Guggulu contains ferulic acids, phenols, and other non-phenolic aromatic acids which are potent scavengers of superoxide radicals. The resin also contains volatile oils, diterpenes, and various other steroids, though guggulsterones E and Z are the principal pharmacological markers used for standardization.
Standardization and product variability. Clinical evaluation has used guggulipid standardized to contain 2.5% guggulsterones. However, liquid chromatography has shown that some commercial over-the-counter products contain less or none of claimed guggulsterone content, and standardization of herbal products is therefore warranted.
4. Established Mechanisms of Action
4.1 Farnesoid X Receptor (FXR) Antagonism
Extracts of the resin of the guggul tree lower LDL cholesterol levels in humans. The plant sterol guggulsterone is the active agent in this extract. Guggulsterone is a highly efficacious antagonist of the farnesoid X receptor (FXR), a nuclear hormone receptor that is activated by bile acids. Guggulsterone treatment decreases hepatic cholesterol in wild-type mice fed a high-cholesterol diet but is not effective in FXR-null mice. Thus, inhibition of FXR activation has been proposed as the basis for the cholesterol-lowering activity of guggulsterone.
Conversion of cholesterol to bile acids in the liver is initiated by the rate-limiting enzyme cholesterol 7α-hydroxylase (CYP7A1), and excretion of bile acids from the liver is mediated by the bile salt export pump (BSEP). The expression of CYP7A1 and BSEP is coordinately regulated by a negative feedback and positive feed-forward mechanism through bile acid-mediated activation of FXR.
The picture is mechanistically complex. As an FXR antagonist, guggulsterone's FXR antagonistic effect is rather weak. Z-guggulsterone did not induce CYP7A1 as generally assumed. Instead, this phytosterol significantly induced CES1 (cholesteryl ester hydrolase) and BSEP through transactivation. A study showed that guggulsterone activates the bile salt export pump (BSEP), an efflux transporter which removes cholesterol metabolites and bile acids from the liver. Such up-regulation of BSEP expression by guggulsterone has been proposed as another possible mechanism for its lipid-lowering effects.
4.2 Pregnane X Receptor (PXR) Activation
Guggulsterone has no effect on FXR inhibition of the CYP7A1 gene, but strongly inhibits the human CYP7A1 gene by activation of pregnane X receptor (PXR). These results suggest that guggulsterone inhibits bile acid secretion from hepatocytes into bile and activates PXR to inhibit bile acid synthesis in the liver. Reduced conversion of cholesterol and bile acid excretion may lead to an increase of hepatic cholesterol and a decrease of intestinal cholesterol absorption, resulting in the lowering of serum cholesterol.
4.3 Promiscuous Steroid Receptor Binding
Guggulsterone (GS) is used to treat a variety of disorders in humans, including dyslipidemia, obesity, and inflammation. Its activity has been suggested to be mediated by antagonism of the receptor for bile acids, the farnesoid X receptor (FXR). However, both stereoisomers of the plant sterol, (E)- and (Z)-GS, bind to the steroid receptors at a much higher affinity than to FXR. Both stereoisomers bind to the mineralocorticoid receptor (MR) with a Ki value of approximately 35 nM, which is greater than 100 times more potent than their affinity for FXR. Both (E)- and (Z)-GS also displayed high affinity for other steroid receptors, including the androgen (AR), glucocorticoid (GR), and progesterone receptors (PR), with Ki values ranging from 224 to 315 nM. This broad steroid receptor activity complicates the attribution of clinical effects to any single nuclear receptor pathway.
4.4 NF-κB Pathway Inhibition
GS exerts anti-inflammatory effects through suppression of nuclear factor-κB (NF-κB), which plays a crucial role in inflammatory processes by regulating the expression of diverse proinflammatory proteins, including cyclooxygenase-2 (COX-2). In various preclinical studies, it inhibited NF-κB, an important pathway in the pathophysiology of inflammatory bowel disease (IBD).
4.5 Thyroid Hormone Modulation
A ketosteroid with the structure 4,17(20)trans-pregnandiene-3,16-dione (Z-guggulsterone) was isolated from the oleo-resin of Commiphora mukul and showed a strong thyroid stimulatory action when administered to albino rats. Its administration (1 mg/100 g body weight) brought about an increase in iodine-uptake by thyroid and enhanced activities of thyroid peroxidase and protease as well as oxygen consumption by isolated slices of liver and biceps muscle. Most notably, isolated guggulsterone appears to enhance the activity of deiodinase, an enzyme that powers the conversion of inactive thyroid hormone (T4) into its active (T3) form. These effects have been observed in animal models; human clinical evidence on this mechanism is absent.
4.6 Apoptosis and Anticancer Signaling
GS induces apoptosis by increasing the expression of proapoptotic proteins while decreasing the levels of antiapoptotic proteins (e.g., IAP1, XIAP, Bfl-1/A1, Bcl-2, cFLIP, Survivin). A number of studies have shown that GS strongly inhibits the activation of various survival signaling pathways, including PI3-kinase/AKT, JAK/STAT, and nuclear factor-κB (NF-κB) in various cancer cells. Constitutive activity of NF-κB plays a crucial role in growth and proliferation of malignant cells via regulating expression of several antiapoptotic genes.
4.7 Antioxidant Activity
GS fortifies cellular defense against oxidative stress by inducing the de novo synthesis of the powerful antioxidant enzyme heme oxygenase-1 (HO-1). Additionally, while no marked change in serum thyroxine (T4) concentrations was observed in one animal study, triiodothyronine (T3) concentration and T3/T4 ratio were enhanced following administration of guggulu extract, alongside a concomitant decrease in hepatic lipid peroxidation (LPO), suggesting guggulu-induced increase in T3 concentration is LPO-mediated.
5. Scientific Evidence by Area of Use
5.1 Lipid-Lowering and Cardiovascular Effects
Background and early Indian evidence. Before 2003, most scientific evidence suggested that guggulipid elicits significant reductions in serum total cholesterol, LDL, and triglycerides, as well as elevations in HDL, based on studies published in Indian medical journals. Studies in animal models and human trials demonstrated that guggulsterone improves serum lipoprotein profiles, although there are inconsistent reports.
Pivotal Western RCT (Szapary et al., JAMA 2003). The most rigorously designed prospective trial to date was a double-blind, randomized, placebo-controlled trial. The objective was to study the short-term safety and efficacy of two doses of a standardized guggul extract (guggulipid, containing 2.5% guggulsterones) in healthy adults with hyperlipidemia eating a typical Western diet, using a parallel design conducted between March 2000 and August 2001. Compared with participants randomized to placebo (n = 36), in whom levels of LDL-C decreased by 5%, both standard-dose guggulipid (n = 33) and high-dose guggulipid (n = 34) raised levels of LDL-C by 4% (P = .01 vs placebo) and 5% (P = .006 vs placebo), respectively, at 8 weeks, for a net positive change of 9% to 10%. There were no significant changes in levels of total cholesterol or HDL-C.
A short-term study of gum guggul efficacy in a Western population used standardized GGE at doses of 3,000 mg (75 mg guggulsterones) or 6,000 mg (150 mg guggulsterones) daily for 8 weeks. In contrast to previous beneficial findings, consumption of GGE was associated with increased LDL-cholesterol in both low- and high-dose groups.
Overall evidence strength. The effects of guggulipid in patients with high cholesterol are not clear, with some studies finding cholesterol-lowering effects, and other research suggesting no benefits. A study performed to address guggulsterone effects in humans showed that the compound did not decrease cholesterol levels in patients, and this discrepancy could be caused by species-specific differences in FXR biology. The overall evidence is mixed and currently does not support cholesterol-lowering efficacy in Western populations; earlier Indian studies had methodological limitations and may have used different dietary backgrounds, making direct comparison difficult.
5.2 Anti-Inflammatory Effects
Down-regulation of the expression of inflammatory mediators, including interleukins, transcription factors and cytokines, and hyaluronidase and collagenase enzymes, has been demonstrated for extracts of Commiphora mukul. Extracts of the plant have anti-inflammatory action and inhibit carrageenan-induced rat paw edema in animal models. In a study evaluating the anti-inflammatory effect of guggul, 500 mg of gum guggul was taken three times per day.
The evidence for anti-inflammatory effects in humans is limited and primarily preclinical. Guggulsterone can be used for the treatment of inflammatory bowel disease (IBD), a disease characterized by chronic inflammation and damage in the gastrointestinal tract. In various preclinical studies, it inhibited NF-κB, an important pathway in the pathophysiology of IBD. This review summarizes the preclinical studies on this topic for providing more insights into the mechanism by which guggulsterone exerts its effect. No published human RCTs specifically on IBD were identified.
5.3 Acne (Nodulocystic / Acne Vulgaris)
One small study has shown guggulsterone to be as effective as tetracycline in the treatment of nodulocystic acne. The dose studied for severe (nodulocystic) acne was a twice-daily dose of guggul that contains up to 25 mg of the active ingredients (guggulsterones). Other trials indicate uncertain benefit for cholesterol, and no benefit when taken with Triphala, an Ayurvedic formulation.
Evidence for acne treatment is preliminary and based on small trials. The available human data is limited to small, mostly Indian studies with methodological limitations; independent replication in larger, adequately powered trials is lacking.
5.4 Thyroid Function
One animal study examined the effects of guggulsterone on the thyroid in rats divided into control and guggulsterone groups (1 mg per 100 g of body weight) for 6 days. The treated group showed enhanced thyroid function as demonstrated by increased thyroid iodine uptake and enzyme activity. Thyroid-stimulatory activity—defined as increased thyroid tissue peroxidase and protease activities, and increased 131Iodine uptake by the thyroid gland—was observed in rats following administration of the individual constituent Z-guggulsterone, suggesting it might be the active pharmacological agent inducing this effect. In the NTP study, serum thyroid-stimulating hormone (TSH) concentrations were significantly increased in female rats dosed with 500 or 1,000 mg/kg/day for 28 days. Increased TSH is associated with decreased thyroid function; however, there was no correlative decrease in thyroxine (T4) or T3 concentrations, and these changes were not observed in the 3-month study.
Although animal studies back this use of guggul, there is currently no human research on the use of guggul for thyroid health. Evidence for thyroid effects in humans is therefore absent from the clinical literature, and the animal data are complex and sometimes contradictory.
5.5 Anticancer Properties
Based on systematic review, guggulsterone significantly affected pancreatic cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, cholangiocarcinoma, esophageal adenocarcinoma, prostate cancer, colon cancer, breast cancer, gastric cancer, colorectal cancer, bladder cancer, glioblastoma, histiocytic leukemia, acute myeloid leukemia, and non-small cell lung cancer in cell line models, by inducing apoptotic pathways, inhibiting cell proliferation, and regulating the expression of genes involved in apoptosis.
In meta-analysis, cancer cells treated with guggulsterone for 24 hours showed an odds ratio of 3.984 (CI 3.263 to 4.865, p < 0.001) compared to control. When cells were exposed to different concentrations of guggulsterone for t > 24 hours, the odds ratio reported was 11.171 (CI 9.148 to 13.643, p < 0.001). This shows that guggulsterone induces apoptosis in a time-dependent manner.
Another mechanism of guggulsterone activity is the reversal of P-glycoprotein-mediated multidrug resistance. Not only does GS induce apoptosis in cancer cells and inhibit cell proliferation, but it is also useful in reducing the cytotoxicity associated with conventional chemotherapeutic agents by sensitizing or causing additive apoptotic effects. Despite extensive study, the conclusive mechanisms responsible for its anticancer effects are still not fully understood.
Limitation: All current anticancer evidence is derived from in vitro cell line studies and a 2023 systematic review and meta-analysis of those in vitro studies. No human clinical trials on guggulsterone for cancer have been identified in the peer-reviewed literature. The evidence is therefore entirely preclinical and cannot be extrapolated to clinical outcomes.
5.6 Obesity and Metabolic Effects
Guggulsterone has been shown to inhibit adipocyte differentiation and lipid storage. Hypoglycemic and hypolipidemic effects may occur following the consumption of guggulsterones. Animal studies have shown guggulsterones to inhibit maturation of adipocyte precursor cells. Increased serum triiodothyronine (T3) and T3/T4 (total thyroxine) ratios were measured in mice administered 0.2 g/kg GGE (approximately 11.5% guggulsterones) orally for 15 days, and this study also found that GGE significantly decreased hepatic lipid peroxidation. Human evidence on body weight or body composition effects is very limited; no large-scale human RCTs were identified.
6. Body Systems and Health Areas
- Cardiovascular system: Lipid metabolism, cholesterol regulation via FXR/PXR pathways, bile acid homeostasis, and triglyceride reduction in animal models.
- Hepatobiliary system: Guggulsterone is an effective antagonist of farnesoid X receptor (FXR), and via this pathway can regulate bile acid synthesis and carbohydrate metabolism.
- Immune/inflammatory system: Inhibition of NF-κB and downstream proinflammatory cytokines; preclinical evidence relevant to arthritis, IBD, and inflammatory conditions.
- Endocrine system (thyroid): Z-guggulsterone shown in animal studies to stimulate thyroid peroxidase and iodine uptake; proposed role in T4-to-T3 conversion.
- Dermatological: Studied in nodulocystic and acne vulgaris; proposed anti-inflammatory and sebum-modulating effects.
- Oncological (preclinical only): Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down-regulation of antiapoptotic gene products; modulates the expression of gene products involved in metastasis (MMP-9, COX-2, and VEGF); and mediates gene expression through modulation of several transcription factors, including NF-κB, STAT3, C/EBPα, androgen receptor, and glucocorticoid receptors.
- Metabolic/adipose: Inhibition of adipocyte differentiation and lipid storage in in vitro and animal models.
7. Dosage Forms and Dosages Reported in Studies
Standardized extract. A US clinical trial used guggulipid containing 2.5% guggulsterones. In a US clinical trial of hyperlipidemia, 75 to 150 mg of standardized guggulsterones were administered daily. This corresponded to 3,000 mg (75 mg guggulsterones) or 6,000 mg (150 mg guggulsterones) of the extract administered daily for 8 weeks.
Anti-inflammatory studies. In a study evaluating the anti-inflammatory effect of guggul, 500 mg of gum guggul was taken three times per day.
Acne. For severe (nodulocystic) acne, the dose studied was a twice-daily dose of guggul containing up to 25 mg of the active guggulsterones.
Animal thyroid studies. In rat studies, Z-guggulsterone was administered at 1 mg per 100 g body weight, bringing about an increase in iodine uptake by the thyroid and enhanced activities of thyroid peroxidase and protease.
NTP toxicology study dosage range. No adverse effects were observed in subchronic and chronic toxicity studies in rats, dogs, or rhesus monkeys administered a standardized GGE containing 2.5–7% Z- and E-guggulsterone (125–500 mg/kg) for 90–180 days.
Forms available. Guggulsterone is available commercially as standardized guggulipid extract in tablet and capsule forms, typically standardized to 2.5% or 5% total guggulsterones. Raw resin preparations (gum guggulu) are used in traditional Ayurvedic formulations. However, liquid chromatography has shown commercial over-the-counter products may contain less or none of the claimed guggulsterone content, underscoring the need for standardization verification.
8. Safety Considerations and Drug Interactions
8.1 General Tolerability in Clinical Studies
While the human safety profile of the extract has not been well described for children, pregnant or breast-feeding women, or patients with severe hepatic or renal disease, little to no adverse events have been reported in clinical studies; the adverse effects were primarily GI-related (diarrhea, nausea), as well as cases of hypersensitivity, possible thyroid problems, headache, hiccough, and rash.
8.2 Thyroid Interactions
Guggul might increase thyroid hormone in the body; taking guggul along with thyroid hormone pills might increase the effects and side effects of thyroid hormones. Conversely, Medscape interaction data indicate guggul may decrease the effects of levothyroxine by pharmacodynamic antagonism, though the significance is classified as minor/unknown. The interaction between guggul and thyroid medications is thus bidirectionally complex and not yet fully characterized.
8.3 Cardiovascular Drug Interactions
Guggul may decrease the serum concentration of diltiazem (monitor therapy). Guggul may also decrease the serum concentration of propranolol (monitor therapy). Guggul decreases levels of propranolol by inhibition of GI absorption; this applies only to the oral form of both agents.
8.4 CYP3A and P-glycoprotein Interactions
Both the tested GGE formulation and individual guggulsterone isomers increased human P-glycoprotein (Pgp) ATPase activity, suggesting that guggulsterone constituents may be substrates for the human Pgp transporter. GGE formulation treatment also significantly attenuated taurocholate uptake in hNTCP assays, suggesting effects on bile acid uptake/excretion pathways. These transporter and metabolic enzyme interactions suggest potential for pharmacokinetic drug interactions with agents metabolized via CYP3A or transported by P-glycoprotein.
8.5 Pregnancy and Lactation
Information regarding safety and efficacy in pregnancy and lactation is lacking.
8.6 Preclinical Toxicology
No adverse effects were observed in subchronic and chronic toxicity studies in rats, dogs, or rhesus monkeys administered a standardized GGE containing 2.5–7% Z- and E-guggulsterone (125–500 mg/kg) for 90–180 days. No mortality was observed in dogs administered 1 g GGE daily for 3 months. Rats administered GGE (250 mg/kg) daily for 3 months had a mortality rate of 50%, relative to 20% in controls. The elevated rodent mortality at high doses warrants attention, though species-specific differences in metabolism and sensitivity make direct human extrapolation unreliable.
8.7 Hypersensitivity and Skin Reactions
Allergic contact dermatitis to guggul extract contained in an anticellulite gel-cream has been reported. Skin hypersensitivity reactions have been noted in several clinical studies, typically presenting as rash.
8.8 Product Standardization Concerns
Owing to its multifarious medicinal and therapeutic values as well as its various other significant bioactivities, guggulsterone has high demand in pharmaceutical, perfumery, and incense industries. There is great demand for large amounts of guggulsterone for further in vitro and in vivo studies. As this demand is not met by natural sources, which only provide the compounds in low yield, synthetic mechanisms were recently developed for the synthesis of this important sterol to make it available in sufficient quantities. The resulting high demand combined with supply limitations heightens the likelihood of adulterated or understandardized commercial products.
References
Go back